NR3C2 and hydrops fetalis: <h4>Aims</h4>The non-steroidal mineralocorticoid receptor agonist (MRA) finerenone reduced heart failure events and cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) in a frequentist analysis of the FINEARTS-HF trial.